Papillary Renal Cell Carcinoma Type 2 research hub

Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

This study is looking at a new way to treat a type of kidney cancer called papillary renal cell carcinoma type 2. It's testing two common cancer drugs, axitinib and pembrolizumab, either alone or together, to see if they can help stop the cancer from growing.